Open AccessA controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus
Author(s) -
Klippel John H,
Karsh Jacob,
Stahl Neil I,
Decker John L,
Steinberg Alfred D,
Schiffman Gerald
Publication year - 1979
Publication title -
arthritis & rheumatism
Language(s) - English
Resource type - Journals
eISSN - 1529-0131
pISSN - 0004-3591
DOI - 10.1002/art.1780221201
Subject(s) - medicine , immunogenicity , immunology , vaccination , pneumococcal vaccine , serology , placebo , belimumab , pneumococcal polysaccharide vaccine , lupus erythematosus , systemic lupus erythematosus , pneumococcal infections , antibody , disease , streptococcus pneumoniae , pneumococcal disease , microbiology and biotechnology , biology , pathology , alternative medicine , b cell , b cell activating factor , antibiotics
The immunogenicity and potential for disease modification of pneumococcal polysaccharide vaccine in systemic lupus erythematosus were evaluated in a controlled, double‐blind study. Forty patients were randomly chosen to receive an intramuscular injection of either vaccine or placebo. Changes in mean antibody concentrations (nanograms antibody nitrogen per milliliter serum) to 12 type‐specific pneumococcal capsular antigens from prevaccination to one month after vaccination were 177 to 1045 in the vaccine ( P < 0.001) and 164 to 153 in the placebo‐treated patients. In the month after vaccination, neither vaccine nor placebo‐treated patients had a significant change in lupus disease activity as assessed by a composite clinical, laboratory, and serologic index. We conclude that patients with systemic lupus erythematosus can be successfully immunized with pneumococcal vaccine without detectable alterations of the underlying disease.